Prestige Consumer Healthcare Inc. $PBH Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lessened its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 5.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,521,999 shares of the company’s stock after selling 93,997 shares during the period. Allspring Global Investments Holdings LLC owned 3.08% of Prestige Consumer Healthcare worth $122,247,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Concurrent Investment Advisors LLC increased its position in Prestige Consumer Healthcare by 7.1% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 4,503 shares of the company’s stock valued at $360,000 after acquiring an additional 300 shares during the period. Inspire Investing LLC increased its position in Prestige Consumer Healthcare by 22.2% in the 2nd quarter. Inspire Investing LLC now owns 4,890 shares of the company’s stock valued at $390,000 after acquiring an additional 888 shares during the period. Callan Family Office LLC acquired a new position in Prestige Consumer Healthcare in the 2nd quarter valued at about $566,000. Blair William & Co. IL increased its position in Prestige Consumer Healthcare by 7.4% in the 2nd quarter. Blair William & Co. IL now owns 113,941 shares of the company’s stock valued at $9,098,000 after acquiring an additional 7,827 shares during the period. Finally, KLP Kapitalforvaltning AS increased its position in Prestige Consumer Healthcare by 2.8% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 18,500 shares of the company’s stock valued at $1,477,000 after acquiring an additional 500 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PBH. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Wednesday, September 24th. Wall Street Zen cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 4th. Canaccord Genuity Group dropped their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Hold” and a consensus price target of $94.80.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $61.83 on Tuesday. Prestige Consumer Healthcare Inc. has a 1 year low of $60.15 and a 1 year high of $90.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The stock’s 50 day moving average price is $65.02 and its 200 day moving average price is $75.91. The firm has a market cap of $3.04 billion, a P/E ratio of 14.51, a PEG ratio of 1.93 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $249.53 million for the quarter, compared to analysts’ expectations of $260.71 million. During the same period in the prior year, the company earned $0.90 EPS. The company’s revenue for the quarter was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.